Albertsons Companies Inc (ACI) Stock Price Today
Aura AI Summary
Key Stats
- $5.62BMarket Cap
- -Volume
- Consumer StaplesSector
- $19.8652W High
- $11.0352W Low
- -Typical Hold Time
- $21.03BEnterprise Value
- 5.87%Div Yield
- -Trading Activity
Track Albertsons Companies Inc (ACI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Albertsons Companies Inc has traded between a low of $11.03 and a high of $19.86, highlighting its annual price range. Buy and sell Albertsons Companies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Most Recent News
New AI tech cuts energy use up to 50% and boosts server capacity on existing NVIDIA hardware.
Trust Carbon Infrastructure unveiled its HXS compute-efficiency layer, which reduces energy consumption by up to 50.5% and increases server throughput by 167% on NVIDIA H100 GPUs without changing AI model outputs. Tested on models from Alibaba, Meta,...
FDA clears Medicus Pharma's Phase 2b trial for SkinJect to treat Gorlin syndrome patients
Medicus Pharma received FDA clearance to start a Phase 2b clinical trial for SkinJect, a minimally invasive treatment targeting basal cell carcinoma in Gorlin syndrome patients. This rare genetic disorder causes multiple basal cell lesions, with no c...
Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.
Collegium Pharmaceutical is transforming from a pain-management company to a central nervous system (CNS) platform by acquiring AZSTARYS, an ADHD drug franchise. The $650 million acquisition, funded by cash and debt, is projected to generate $60–70 m...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.